In a pharmaceutical sector under increasing budgetary pressure, Market Access planning has become a strategic lever. Department alignment, anticipation of price/volume/mix effects, discount modeling—expectations are rising, while adequate tools are often missing. But with Anaplan and Beyond Plans, pharmaceutical companies can implement more precise, collaborative, and results-oriented commercial planning.

Navigating a Complex and Restrictive Environment

Increasingly selective healthcare policies, frequent regulatory changes, conditional discounts, fixed budgets, and multiple stakeholders… In this context, planning a drug launch has become a discipline in its own right.

To succeed, Market Access, Finance, Business Development, and Supply Chain departments must collaborate seamlessly. However, organizational silos, disconnected Excel files, and the lack of a shared planning tool make the task even more complex. The consequences? Unreliable forecasts, poorly anticipated margins, and missed opportunities.

Anaplan: Modeling Scenarios and Business Impact

Deployed by Beyond Plans, the Anaplan platform enables pharmaceutical companies to centralize all dimensions of a product launch plan:

• Forecasted volumes by therapeutic indication,
• Modeling of pricing grids and conditional discounts (e.g., volume-based rebates, performance-based agreements),
• Analysis of price/volume/mix effects on net revenue,
• Multi-country scenarios incorporating reference pricing rules or domino effects,
• Anticipation of impacts on production and the supply chain.

All within a secure, collaborative, and real-time environment.

Client Case: Roche Anticipates Net Margins as Early as the Negotiation Phase

At a leading pharmaceutical company in France, Beyond Plans implemented an Anaplan model allowing the Market Access team to:

• Simulate various negotiated pricing scenarios in advance,
• Measure the impact of these scenarios on net margins after applying discounts,
• Share these simulations with Finance and Supply teams to adjust production plans accordingly.

The result: informed decisions, stronger negotiation capabilities, and better lifecycle management of the product.

What Are the Benefits for Pharma Companies?

• Reduced uncertainty: The ability to test multiple hypotheses quickly helps secure projections.
• Improved collaboration: Finance, Market Access, Sales, and Operations work from a unified source of truth.
• Faster time-to-market: Better coordination leads to reduced launch timelines.
• Higher margins: Optimizing volumes and commercial conditions helps maximize the value of each product launch.

Beyond Plans: A Strategic Partner for Pharma

With deep knowledge of the pharmaceutical sector and certified expertise in Anaplan, Beyond Plans helps companies build custom planning models aligned with their business, regulatory, and financial constraints. Together, we turn your data into performance drivers—for your products, your teams… and your patients.